Moreover, results showed that the generated MART-1-recognizing CD8+ T cells were fully functional and capable of recognizing and killing melanoma tumor cells, as effectively as MART-1 specific CD8+ T cells primed by MART-126–35L peptide-pulsed DCs. The gene discussed is CD8A; the disease is neoplasm.